g70 press release 1 for immediate march 15 2001 pliva group 2000 results highlights gd8 overall revenue growth of 18 7 or 21 3 excluding yeast business to hrk 4 963 9 m rising international revenues reach 515 and 70 8 confirming s commitment greater internationalisation azithromycin 27 765 a significant 64 increase in r&d costs 362 advances top three research projects into phase i clinical trials allows the development over 40 generics pipeline acquires uk based dominion pharma limited usd 5 as part its strategy enter key western markets with finished drug forms divestments non core businesses include sale operations kvasac doo lachema blansko exceptional proceeds 108 from zagreba?ka banka zaba shares an overpaid royalty tax return 96 which respectively earnings before net income one time severance
